<DOC>
	<DOCNO>NCT00313534</DOCNO>
	<brief_summary>RATIONALE : Nordihydroguaiaretic acid may stop growth tumor cell block enzymes need cell growth . PURPOSE : This phase I trial study side effect best dose nordihydroguaiaretic acid treat patient nonmetastatic relapsed prostate cancer .</brief_summary>
	<brief_title>Nordihydroguaiaretic Acid Treating Patients With Nonmetastatic Relapsed Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose nordihydroguaiaretic acid ( NDGA ) patient nonmetastatic , biochemically relapsed prostate cancer . Secondary - Determine prostate-specific antigen-modulating effect NDGA patient . OUTLINE : This dose-escalation study . Patients receive oral nordihydroguaiaretic acid ( NDGA ) twice daily day 1-28 . Treatment repeat every 28 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos NDGA maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PROJECTED ACCRUAL : A total 30 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Masoprocol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm prostate cancer , meet 1 follow criterion : Androgendependent disease ( testosterone ≥ 250 ng/mL ) Androgenindependent disease ( testosterone &lt; 50 ng/mL ) Received prior definitive therapy primary prostate cancer comprise follow : Externalbeam radiotherapy without hormonal therapy Brachytherapy without pelvic externalbeam radiotherapy hormonal therapy Radical prostatectomy without adjuvant salvage radiotherapy Cryotherapy Must evidence disease progression , evidence elevate prostatespecific antigen ( PSA ) rise serially postdefinitive therapy nadir 2 determination take ≥ 1 week apart Elevated PSA , meet 1 follow criterion : At least 1.0 ng/mL post radiotherapy cryotherapy At least 4 ng/mL post radical prostatectomy Must show disease progression discontinuation antiandrogen ( patient androgendependent disease receive antiandrogen part primary androgen ablation ) No metastatic disease , confirm negative bone scan negative CT scan MRI abdomen/pelvis PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Absolute neutrophil count ≥ 1,500/mm³ Hemoglobin ≥ 8.0 g/dL Platelet count ≥ 100,000/mm³ Creatinine ≤ 1.5 time upper limit normal ( ULN ) Bilirubin ≤ 1.5 time ULN AST ≤ 1.5 time ULN No medical condition would interfere study therapy compliance No active malignancy except previously treat squamous cell basal cell skin cancer cancer treat consider &lt; 30 % risk relapse Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : See Disease Characteristics More 8 week since prior strontiumchloride Sr 89 More 4 week since first dose bisphosphonates More 4 week since prior major surgery radiotherapy At least 4 week since prior hormonal agent , include megestrol steroid Concurrent luteinizing hormonereleasing hormone analog allow maintain castrate level testosterone At least 4 week since prior concurrent saw palmetto , finasteride , herbal agent intend low PSA Prior adjuvant neoadjuvant androgendeprivation therapy allow androgendependent prostate cancer provide follow met : No 8 month androgen deprivation At least 12 month since last day effective androgen deprivation Testosterone &gt; 250 ng/mL enrollment Prior hormonal therapy , chemotherapy , investigational therapy biochemical relapse allow No concurrent chemotherapeutic , immunotherapeutic , investigational agent No concurrent radiotherapy No concurrent filgrastim ( GCSF ) sargramostim ( GMCSF )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>recurrent prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage I prostate cancer</keyword>
</DOC>